Drug Profile


Alternative Names: Antithrombin III - modified

Latest Information Update: 12 Mar 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Hospital Boston
  • Class Antineoplastics; Antithrombins; Biological proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 12 Mar 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 27 Oct 1999 Preclinical data have been added to the pharmacodynamics section
  • 23 Sep 1999 Genzyme Molecular Oncology and ATIII LLC have entered a joint development agreement for aaATIII
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top